Yes, but those are largely irrelevant as they are just exercising the option & cashing it right in. That is materially different than changing their position.
Watching the charts, large blocks trade only on an uptick which indicates there is some strong shorting going on over the past week. It doesn't look like any of the institutional shareholders are liquidating but rather some strong shorts moving in (on AEGR as well as many other stocks) in preparation for a broad market downturn.
The interesting part of that is there is no indication when that broad market downturn might be. The downturn is based on the run up in the DOW, but stocks like AEGR aren't part of the DOW so not directly affected. Affected indirectly as they go with the overall market flow, but at least we know there is nothing wrong with AEGR in itself.
So answer the question.
Do you have any position whatsoever (long or short) in AEGR.
You dance around it and pretend to answer everything else that wasn't asked, why are you so petrified with fear over answering what was asked of you.
Are you secretly employed by the Obama administration?
Bring this out into the open again instead of letting you hide 14 levels deep.
I've answered all the questions put to me, and really have only asked you ONE question, but you still continue to duck & hide.
Do you own shares long, short, or have no position in AEGR whatsoever?
Please answer the question.
I have answered all questions put to me.
You are the one who keeps ducking the question.
And there really is only one question out there for you.
So what are you so dearly afraid of? LOL.
Your silence speaks volumes.
Jetmanbash, for someone who pretends to have a target of $1,000+ on this stock, you are highly critical of all aspects of it - almost like you were lying.
What is your position? Do you own shares long or short or none whatsoever?
Thompson-Reuters updates monthly and the last update pulled into Yahoo Finance under Key Statistics was on 10/31/2013.
I thought you always claimed it was a worldwide conspiracy to trick you into shorting, then pump the price to $10,000/share and force you to cover then. What happened to all that nonsense you used to spew?
Arthur - go ahead and short here then if you have any money left.
P/E is a relative measure only and in the context of the growth rate, AEGR is incredibly cheap.
Consensus EPS for 2014 is $1.81/share. So at $67.30/share that is a P/E of 37.
If they beat and hit the high analyst estimate of $3/share, then that is a P/E of 22.
Cheap no matter how you look at it.
P/E of 30.
400% growth rate of earnings (not revenues, just earnings) 2014 over 2013.
All the fundamentals are in tact.
Not everyone, just YOU Arthur. Just you.
I still want to pick up more shares, just waiting to be sure it bottomed.
With EPS in 2014 projected to be ~$2/share this stock is trading at a P/E of 32 and a growth rate of 400%. Extremely undervalued.
Compared to you, who doesn't have any position in the stock whatsoever and is just here out of bitterness & hatred?
Takes one to know one and there certainly is no bigger douche bag around than you.
Which is well known, well documented, and already labeled with a warning on the box.
The liver issues are well documented and old news, as is the co-medications used to support normal liver operation.
To summarize, the Phase 3 study of Juxtapid showed continued success in meeting primary endpoints for efficacy over a longer time horizon while keeping the same safety profile as they did at 78 weeks. This shows that longer term use continues to be effective (whereas many medications taper off substantially the longer you use them).
So, continued effectiveness over a longer period of time, stable safety profile (same as before, just now with a longer time horizon), and continued success.
Oh, and one person had to discontinue, who was an alcoholic, but even that provides useful data. Few medications are even remotely tolerated when an excess of alcohol is introduced. So this is no surprise.
The adverse event (AE) profile observed in the extension study was consistent with that observed during the pivotal trial. Gastrointestinal symptoms were the most common AE, reported in 63% (12/19) of patients in the extension study. Transient aminotransferase elevations (ALT or AST) =3x the upper limit of normal (ULN) occurred in nine of the patients who completed Week 126 of the extension study either in the pivotal phase or the extension phase or both, including five patients who had elevations =5x ULN. Of these patients, one patient had an ALT elevation of 24x ULN that was reversible with temporary suspension of lomitapide, and a second patient had a reversible ALT elevation of =10--20x ULN following co-administration of other drugs that may precipitate liver injury or interact with lomitapide. One patient who used excessive alcohol was withdrawn due to persistent ALT elevations =5x ULN. No Hy's law cases were reported.
Juxtapid isn't intended to treat coronary heart failure, and while it was an unfortunate event, they at least let the 58-year old patient in the study anyway (as they should IMHO, they should never stop someone from at least getting some relief even if something else (another disease) intervenes and takes over.